<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Amgen Inc — News on 6ix</title>
<link>https://6ix.com/company/amgen-inc</link>
<description>Latest news and press releases for Amgen Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 24 Apr 2026 20:01:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/amgen-inc" rel="self" type="application/rss+xml" />
<item>
<title>AMGEN ANNOUNCES WEBCAST OF 2026 FIRST QUARTER FINANCIAL RESULTS</title>
<link>https://6ix.com/company/amgen-inc/news/amgen-announces-webcast-of-2026-first-quarter-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/amgen-inc/news/amgen-announces-webcast-of-2026-first-quarter-financial-results</guid>
<pubDate>Fri, 24 Apr 2026 20:01:00 GMT</pubDate>
<description>Amgen (NASDAQ:AMGN) today announced that it will report its first quarter 2026 financial results on Thursday, April 30, 2026, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.</description>
</item>
<item>
<title>AMGEN ANNOUNCES RETIREMENT OF DAVID M. REESE, EXECUTIVE VICE PRESIDENT AND CHIEF TECHNOLOGY OFFICER</title>
<link>https://6ix.com/company/amgen-inc/news/amgen-announces-retirement-of-david-m-reese-executive-vice-president-and-chief-technology-officer</link>
<guid isPermaLink="true">https://6ix.com/company/amgen-inc/news/amgen-announces-retirement-of-david-m-reese-executive-vice-president-and-chief-technology-officer</guid>
<pubDate>Wed, 22 Apr 2026 20:00:00 GMT</pubDate>
<description>Amgen (NASDAQ:AMGN) today announced the retirement of David M. Reese, M.D., executive vice president and Chief Technology Officer, effective June 30, 2026.</description>
</item>
<item>
<title>AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR SUBCUTANEOUS TEPEZZA® IN ADULTS LIVING WITH MODERATE-TO-SEVERE ACTIVE THYROID EYE DISEASE</title>
<link>https://6ix.com/company/amgen-inc/news/amgen-announces-positive-topline-phase-3-results-for-subcutaneous-tepezzar-in-adults-living-with-moderate-to-severe-active-thyroid-eye-disease</link>
<guid isPermaLink="true">https://6ix.com/company/amgen-inc/news/amgen-announces-positive-topline-phase-3-results-for-subcutaneous-tepezzar-in-adults-living-with-moderate-to-severe-active-thyroid-eye-disease</guid>
<pubDate>Mon, 06 Apr 2026 04:00:00 GMT</pubDate>
<description>Primary and Key Secondary Endpoints Met 77% of Patients Achieved Highly Statistically Significant Proptosis Response Study Showed Clinically Meaningful</description>
</item>
<item>
<title>Zai Lab Announces Global Clinical Trial Collaboration and Supply Agreement to Evaluate Novel DLL3 ADC, Zocilurtatug Pelitecan, in Combination with a Bispecific T-cell Engager Therapy</title>
<link>https://6ix.com/company/amgen-inc/news/zai-lab-announces-global-clinical-trial-collaboration-and-supply-agreement-to-evaluate-novel-dll3-adc-zocilurtatug-pelitecan-in-combination-with-a-bispecific-t-cell-engager-therapy</link>
<guid isPermaLink="true">https://6ix.com/company/amgen-inc/news/zai-lab-announces-global-clinical-trial-collaboration-and-supply-agreement-to-evaluate-novel-dll3-adc-zocilurtatug-pelitecan-in-combination-with-a-bispecific-t-cell-engager-therapy</guid>
<pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
<description>- Collaboration with Amgen to explore the clinical potential of Zai Lab’s DLL3-targeting ADC, zocilurtatug pelitecan, in combination with Amgen’s IMDELLTRA®</description>
</item>
<item>
<title>REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS</title>
<link>https://6ix.com/company/amgen-inc/news/repathar-cuts-risk-of-first-major-cardiovascular-events-by-31percent-in-high-risk-patients-without-known-significant-atherosclerosis</link>
<guid isPermaLink="true">https://6ix.com/company/amgen-inc/news/repathar-cuts-risk-of-first-major-cardiovascular-events-by-31percent-in-high-risk-patients-without-known-significant-atherosclerosis</guid>
<pubDate>Sat, 28 Mar 2026 04:00:00 GMT</pubDate>
<description>Repatha is the Only PCSK9 Inhibitor to Significantly Reduce the Risk of First CV Events in High-Risk Primary PreventionVESALIUS-CV Subgroup Findings Reinforce</description>
</item>
<item>
<title>AMGEN TO PRESENT AT THE LEERINK PARTNERS 2026 GLOBAL HEALTHCARE CONFERENCE</title>
<link>https://6ix.com/company/amgen-inc/news/amgen-to-present-at-the-leerink-partners-2026-global-healthcare-conference-29</link>
<guid isPermaLink="true">https://6ix.com/company/amgen-inc/news/amgen-to-present-at-the-leerink-partners-2026-global-healthcare-conference-29</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>THOUSAND OAKS, Calif., March 5, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Leerink Partners 2026 Global Healthcare Conference at 9:20 a.m.</description>
</item>
<item>
<title>AMGEN ANNOUNCES 2026 SECOND QUARTER DIVIDEND</title>
<link>https://6ix.com/company/amgen-inc/news/amgen-announces-2026-second-quarter-dividend-46</link>
<guid isPermaLink="true">https://6ix.com/company/amgen-inc/news/amgen-announces-2026-second-quarter-dividend-46</guid>
<pubDate>Wed, 04 Mar 2026 05:00:00 GMT</pubDate>
<description>THOUSAND OAKS, Calif., March 4, 2026 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.52 per share dividend for</description>
</item>
<item>
<title>AMGEN TO PRESENT AT THE 46TH ANNUAL TD COWEN HEALTH CARE CONFERENCE</title>
<link>https://6ix.com/company/amgen-inc/news/amgen-to-present-at-the-46th-annual-td-cowen-health-care-conference</link>
<guid isPermaLink="true">https://6ix.com/company/amgen-inc/news/amgen-to-present-at-the-46th-annual-td-cowen-health-care-conference</guid>
<pubDate>Tue, 24 Feb 2026 21:01:00 GMT</pubDate>
<description>Amgen (NASDAQ:AMGN) will present at the 46th Annual TD Cowen Health Care Conference at 1:10 p.m. ET on Monday, March 2, 2026. Kave Niksefat, senior vice president of Global Marketing and Access at Amgen, and Justin Claeys, senior vice president of Finance at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.</description>
</item>
<item>
<title>MATTERWORKS, INC. ANNOUNCES UPDATE TO LEADERSHIP TEAM</title>
<link>https://6ix.com/company/amgen-inc/news/matterworks-inc-announces-update-to-leadership-team</link>
<guid isPermaLink="true">https://6ix.com/company/amgen-inc/news/matterworks-inc-announces-update-to-leadership-team</guid>
<pubDate>Tue, 17 Feb 2026 16:30:00 GMT</pubDate>
<description>Matterworks, Inc., a frontier AI company providing predictive biology tools that accelerate discovery, development and manufacturing across life science applications, announced that Paul Stone has joined the company as Chief Financial Officer and Head of Corporate Development. Mr. Stone is a life sciences executive with over twenty-eight years of experience and leadership roles in venture capital and operating companies. He joins Matterworks from 5AM Ventures (Partner), following his most recent</description>
</item>
<item>
<title>AMGEN TO PRESENT AT CITI'S 2026 VIRTUAL ONCOLOGY LEADERSHIP SUMMIT</title>
<link>https://6ix.com/company/amgen-inc/news/amgen-present-citis-2026-virtual-210100489</link>
<guid isPermaLink="true">https://6ix.com/company/amgen-inc/news/amgen-present-citis-2026-virtual-210100489</guid>
<pubDate>Fri, 13 Feb 2026 21:01:00 GMT</pubDate>
<description>Amgen (NASDAQ:AMGN) will present at Citi's 2026 Virtual Oncology Leadership Summit at 12:15 p.m. PT on Wednesday, Feb. 18, 2026. Jean-Charles Soria, senior vice president of oncology within global development at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.</description>
</item>
<item>
<title>BioPhorum announces formation of Strategic Advisory Board to accelerate industry collaboration</title>
<link>https://6ix.com/company/amgen-inc/news/biophorum-announces-formation-of-strategic-advisory-board-to-accelerate-industry-collaboration</link>
<guid isPermaLink="true">https://6ix.com/company/amgen-inc/news/biophorum-announces-formation-of-strategic-advisory-board-to-accelerate-industry-collaboration</guid>
<pubDate>Thu, 05 Feb 2026 09:00:00 GMT</pubDate>
<description>BioPhorum, the pharmaceutical industry's most trusted collaborative network for change, today announces the formation of its inaugural Strategic Advisory Board.</description>
</item>
<item>
<title>AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS</title>
<link>https://6ix.com/company/amgen-inc/news/amgen-reports-fourth-quarter-full-210100986</link>
<guid isPermaLink="true">https://6ix.com/company/amgen-inc/news/amgen-reports-fourth-quarter-full-210100986</guid>
<pubDate>Tue, 03 Feb 2026 21:01:00 GMT</pubDate>
<description>Amgen (NASDAQ: AMGN) today announced financial results for the fourth quarter and full year of 2025 versus the comparable periods in 2024.</description>
</item>
<item>
<title>AMGEN ANNOUNCES WEBCAST OF 2025 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS</title>
<link>https://6ix.com/company/amgen-inc/news/amgen-announces-webcast-2025-fourth-210100316</link>
<guid isPermaLink="true">https://6ix.com/company/amgen-inc/news/amgen-announces-webcast-2025-fourth-210100316</guid>
<pubDate>Wed, 28 Jan 2026 21:01:00 GMT</pubDate>
<description>Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2025 financial results on Tuesday, February 3, 2026, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.</description>
</item>
<item>
<title>Biocom Announces Powerhouse Keynote Panel Featuring Heads of Discovery and Research & Development from AbbVie, Amgen and Eli Lilly at 2026 Global Partnering & Investor Conference</title>
<link>https://6ix.com/company/amgen-inc/news/biocom-announces-powerhouse-keynote-panel-featuring-heads-of-discovery-and-research-and-development-from-abbvie-amgen-and-eli-lilly-at-2026-global-partnering-and-investor-conference-1</link>
<guid isPermaLink="true">https://6ix.com/company/amgen-inc/news/biocom-announces-powerhouse-keynote-panel-featuring-heads-of-discovery-and-research-and-development-from-abbvie-amgen-and-eli-lilly-at-2026-global-partnering-and-investor-conference-1</guid>
<pubDate>Wed, 21 Jan 2026 14:02:00 GMT</pubDate>
<description>SAN DIEGO, January 21, 2026--Biocom today announced a distinguished keynote session for its 2026 Global Partnering & Investor Conference, taking place February 24 to 26 at The Lodge at Torrey Pines in La Jolla, California.</description>
</item>
<item>
<title>Ember LifeSciences appoints Ann Hyllengren as Chief Financial Officer</title>
<link>https://6ix.com/company/amgen-inc/news/ember-lifesciences-appoints-ann-hyllengren-as-chief-financial-officer</link>
<guid isPermaLink="true">https://6ix.com/company/amgen-inc/news/ember-lifesciences-appoints-ann-hyllengren-as-chief-financial-officer</guid>
<pubDate>Wed, 21 Jan 2026 13:00:00 GMT</pubDate>
<description>Following its recent $16.5 million Series A financing in December, Ember LifeSciences, Inc., a leading provider of revolutionary cold chain technology, announced the appointment of Ann Hyllengren as Chief Financial Officer to support the company's next phase of growth.</description>
</item>
<item>
<title>RO ANNOUNCES RESEARCH COLLABORATION TO BETTER UNDERSTAND AND IMPROVE THE REAL-WORLD PATIENT EXPERIENCE WITH GLP-1S</title>
<link>https://6ix.com/company/amgen-inc/news/ro-announces-research-collaboration-to-better-understand-and-improve-the-real-world-patient-experience-with-glp-1s</link>
<guid isPermaLink="true">https://6ix.com/company/amgen-inc/news/ro-announces-research-collaboration-to-better-understand-and-improve-the-real-world-patient-experience-with-glp-1s</guid>
<pubDate>Tue, 13 Jan 2026 13:00:00 GMT</pubDate>
<description>Ro, the leading direct-to-patient healthcare company, today announced a research collaboration with Amgen to study barriers to care and patients' treatment experience. Powered by data from Ro's nationwide platform, the research will evaluate the real-world challenges that patients and providers must navigate in order to access and deliver evidence-based obesity care.</description>
</item>
<item>
<title>AMGEN TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE</title>
<link>https://6ix.com/company/amgen-inc/news/amgen-present-44th-annual-j-210100247</link>
<guid isPermaLink="true">https://6ix.com/company/amgen-inc/news/amgen-present-44th-annual-j-210100247</guid>
<pubDate>Wed, 07 Jan 2026 21:01:00 GMT</pubDate>
<description>Amgen (NASDAQ:AMGN) will present at the 2026 J.P. Morgan Healthcare Conference at 3:45 p.m. PT on Monday, January 12, 2026. Robert A. Bradway, chairman and chief executive officer at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.</description>
</item>
<item>
<title>AMGEN ACQUIRES DARK BLUE THERAPEUTICS, BOLSTERING ONCOLOGY PIPELINE</title>
<link>https://6ix.com/company/amgen-inc/news/amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline-2026-01-06</link>
<guid isPermaLink="true">https://6ix.com/company/amgen-inc/news/amgen-acquires-dark-blue-therapeutics-bolstering-oncology-pipeline-2026-01-06</guid>
<pubDate>Tue, 06 Jan 2026 05:00:00 GMT</pubDate>
<description>Acquisition Adds Differentiated Investigational Molecule Designed to Treat Acute Myeloid LeukemiaTHOUSAND OAKS, Calif., Jan. 6, 2026 /PRNewswire/ -- Amgen</description>
</item>
<item>
<title>AMGEN TAKES ACTION WITH THE U.S. GOVERNMENT TO LOWER THE COST OF MEDICINES FOR AMERICAN PATIENTS</title>
<link>https://6ix.com/company/amgen-inc/news/amgen-takes-action-us-government-lower-cost-medicines-american-patients-2025-12-19</link>
<guid isPermaLink="true">https://6ix.com/company/amgen-inc/news/amgen-takes-action-us-government-lower-cost-medicines-american-patients-2025-12-19</guid>
<pubDate>Fri, 19 Dec 2025 05:00:00 GMT</pubDate>
<description>Underscores Long-Standing Commitment to Investing in Innovation and U.S. Manufacturing THOUSAND OAKS, Calif., Dec. 19, 2025 /PRNewswire/ -- Amgen</description>
</item>
<item>
<title>FDA APPROVES UPLIZNA® FOR ADULTS WITH GENERALIZED MYASTHENIA GRAVIS</title>
<link>https://6ix.com/company/amgen-inc/news/fda-approves-upliznar-adults-generalized-myasthenia-gravis-2025-12-11</link>
<guid isPermaLink="true">https://6ix.com/company/amgen-inc/news/fda-approves-upliznar-adults-generalized-myasthenia-gravis-2025-12-11</guid>
<pubDate>Thu, 11 Dec 2025 05:00:00 GMT</pubDate>
<description>UPLIZNA Offers gMG Patients Deep and Durable Symptom Control and Twice-Yearly Dosing*First and Only CD19-Targeted B Cell Therapy Approved in anti-AChR and</description>
</item>
</channel>
</rss>